美沙拉嗪联合培菲康治疗溃疡性结肠炎患者的疗效及对 TLR4、MyD88的影响

目的：观察美沙拉嗪联合培菲康治疗溃疡性结肠炎（UC）的疗效及对患者血清Toll样受体4（TLR4）、髓样分化因子88（MyD88）的影响。方法将86例UC患者按随机数字表法分为观察组和对照组，每组43例；观察组给予美沙拉嗪联合培菲康治疗，对照组单纯给予美沙拉嗪治疗，8周为一疗程；观察两组患者的临床疗效，测定血清中TLR4、MyD88的含量变化，并记录治疗中的不良反应情况。结果观察组临床总有效率（95.35％）明显高于对照组（81.40％），差异有统计学意义（ P ＜0.05）；两组患者血清TLR4、MyD88含量均较治疗前明显下降（ P ＜0.05或P ＜0.01），且观察组TLR4的下降比对照组更为明显（ P ＜0.05）；两组不良反应发生率比较差异无统计学意义（ P ＞0.05）。结论美沙拉嗪联合培菲康治疗UC疗效确切、安全性好，其作用可能与调节外周血TLR4、MyD88的含量有关。

Effects of mesalazine combined with bifico on the treatment of ulcerative colitis and on TLR4 and MyD88

Objective To investigate the clinical efficacy of mesalazine combined with bifico in the treatment of ulcerative co -litis （UC） and its effect on toll-like receptor 4 （TLR4） and myeloid differentiation factor 88 （MyD88）.Methods A total of 86 cases of UC was randomly divided into the observation and control groups with 43 cases in each group .The observation group was given me-salazine combined bifico treatment , and the control group was given mesalazine , and eight weeks as a course of treatment .The clinical efficacy was observed .Serum TLR4 and MyD88 were tested.Adverse reaction in treatment was recorded .Results The total effective rate （95.35%） in observation group was significantly higher than that （81.40%） in control group（ P ＆lt;0.05）.The serum TLR4 and MyD88 after treatment of two groups were significantly lower than that before treatment , respectively （ P ＆lt;0.05 or P ＆lt;0.01 ） , and the decline in TLR4 of observation group was superior to that of control group （ P ＆lt;0.05 ） .The difference of adverse reaction rate in two groups was not significant （ P ＆gt;0.05 ） .Conclusions Mesalazine combined with bifico in the treatment of UC is safe and effective . The effect may be related to regulation of peripheral blood TLR 4 and MyD88 content .